The piggyBac™ transposase technology is a non-viral, gene delivery system designed for use in many different research applications. With a large cargo capacity of over 200kb, piggyBac™ surpasses many other transposon and viral delivery vehicles, making it the optimal choice for stable cell line creation. The high efficiency and stability of piggyBac™ integration events have proven effective in a variety of genomes. To date, over 550 peer-reviewed papers have been published as a result of the piggyBac™ technology. Hera can use the piggyBac™ technology to create stable tumor cell lines for imaging with Luciferase or other reporters (i.e. TK for PET imaging).
How it works:
Mossine VV, Waters JK, Hannink M, Mawhinney TP (2013) piggyBac Transposon plus Insulators Overcome Epigenetic Silencing to Provide for Stable Signaling Pathway Reporter Cell Lines. PLoS ONE 8(12): e85494. doi:10.1371/journal.pone.0085494
Jung, C. J., Ménoret, S., Brusselle, L., Tesson, L., Usal, C., Chenouard, V., . . . Anegon, I. (2016). Comparative Analysis of piggyBac, CRISPR/Cas9 and TALEN Mediated BAC Transgenesis in the Zygote for the Generation of Humanized SIRPA Rats. Sci. Rep. Scientific Reports, 6, 31455. doi:10.1038/srep31455
- PiggyBac Reporter Hep-G2 cell line for high throughput and high sensitivity screening of AhR transcription and study of cytotoxic compounds.
Novotna, A., Petr, P., & Dvorak, Z. (2011). Novel Stably Transfected Gene Reporter Human Hepatoma Cell Line for Assessment of Aryl Hydrocarbon Receptor Transcriptional Activity: Construction and Characterization. Environmental Science & Technology Environ. Sci. Technol., 45(23), 10133-10139. doi:10.1021/es2029334
piggyBac™ is a trademark of Transposagen
Cas-CLOVER™ is a trademark of Poseida Therapeutics